Classification
Product TypeIngredient
Product FormPowder (pharmaceutical-grade lactose, typically crystalline/monohydrate grades)
Industry PositionPharmaceutical excipient / functional ingredient
Market
Pharmaceutical-grade lactose in Costa Rica is primarily used as an excipient by domestic pharmaceutical manufacturers and contract/maquila producers for solid oral dosage forms (e.g., tablets, capsules and sachets). Imports of pharmaceutical products and pharmaceutical raw materials are treated as products of sanitary interest, with Ministry of Health controls routed through Costa Rica’s Single Window (VUCE/PROCOMER) using the relevant Technical Note workflows (e.g., NT57 for medicines/raw materials). For customs classification and tariff context, lactose commonly maps to tariff lines such as HS 17021100 and 17021900, which appear in Costa Rica tariff schedules with a base rate context of 1% (subject to correct classification and any applicable preferential treatment). Buyer acceptance commonly hinges on pharmacopeial compliance and tight specifications (composition, microbiological and impurity controls) for pharmaceutical-grade lactose.
Market RoleImport-dependent consumer market (pharmaceutical excipient)
Domestic RoleIndustrial excipient input for domestic pharmaceutical manufacturing, contract manufacturing and compounding supply chains
Market Growth
Specification
Primary VarietyLactose monohydrate (pharmaceutical grade; multiple particle-size grades)
Secondary Variety- Anhydrous lactose (application-specific)
- Spray-dried lactose grades (application-specific)
Physical Attributes- Pure white, crystalline, free-flowing powder (typical description for pharmaceutical-grade lactose).
- Particle size distribution is a key buyer specification lever and can vary widely by grade (e.g., coarse to superfine; mesh-based commercial grades).
Compositional Metrics- Typical pharmaceutical-grade lactose composition reference: lactose (minimum) 99.8%; protein 0.01%; fat 0%; ash 0.03%; moisture 4.5–5.5%.
- Typical microbiological/impurity expectations cited in supplier guidance include low plate count and negative E. coli/Salmonella, plus residue/impurity controls (supplier- and pharmacopeia-driven).
Grades- Compendial / multi-compendial lactose monohydrate grades (e.g., aligned to U.S./European/Japanese pharmacopeias, depending on supplier).
- Milled and sieved grades differentiated by particle size (e.g., mesh-size graded offerings for flowability, blending, and granulation behavior).
Packaging- Sealed moisture-protective packaging is emphasized in storage/shipping guidance (cool, dry environment; humidity control per supplier recommendations).
Supply Chain
Value Chain- Overseas excipient manufacturer (pharmaceutical-grade lactose) → ocean freight to Costa Rica → customs broker/importer filing → VUCE FAD/Technical Note workflow (NT57) and Ministry of Health controls as applicable → TICA customs processing and potential inspections/scanning → domestic warehousing/distribution → pharmaceutical manufacturer/CMO or compounding pharmacy use.
Temperature- Supplier guidance commonly recommends storing/shipping pharmaceutical-grade lactose in cool, dry conditions (e.g., <27°C and <65% RH cited in one industry guidance source; confirm supplier-specific limits).
Freight IntensityMedium
Transport ModeSea
Risks
Regulatory Compliance HighImport clearance can be blocked or severely delayed if the importer cannot complete the required Ministry of Health controls through VUCE for products/raw materials of sanitary interest (e.g., NT57 workflow where applicable), or if shipment and product-registration details do not align with the VUCE FAD/Technical Note filing and customs requirements.Confirm whether the import is in-scope for NT57 and any linked product-registration prerequisites before shipment; pre-validate FAD data fields (invoice/BOL, tariff code, importer identity, manufacturer name) and keep CoA/quality documentation ready for permit and buyer QA review.
Food Safety MediumPharmaceutical-grade lactose is sourced from dairy streams and must meet strict microbiological and impurity specifications; any deviation (e.g., microbial positives or residue flags) can trigger rejection by pharmaceutical QA and disrupt supply continuity for domestic production runs.Require supplier CoA for each lot, confirm pharmacopeial compliance expectations in the quality agreement, and use approved suppliers with stable change-control and traceability practices.
Logistics MediumOcean-freight and port/clearance variability (including inspections/scanning and documentation checks) can cause lead-time volatility; combined with moisture sensitivity of powders, this can translate into caking/handling issues or production scheduling disruptions for import-dependent users.Use moisture-protective packaging, specify dry storage/shipping conditions, maintain safety stock at the formulation site, and align shipment ETAs with permit/Technical Note readiness to reduce dwell time.
Sustainability- Upstream dairy supply-chain greenhouse-gas (enteric methane) exposure is a relevant sustainability theme for lactose sourcing; Costa Rica’s livestock sector is explicitly linked to national methane/GHG considerations and mitigation policy focus (relevant for ESG-driven procurement screens even when lactose is imported).
Standards- Supplier GMP alignment for pharmaceutical excipients (buyer audit expectations)
- ISO 9001 and/or FSSC 22000 certifications (supplier-dependent; often used as supporting quality-system evidence by excipient producers)
FAQ
What is the main regulatory deal-breaker for importing pharmaceutical-grade lactose into Costa Rica for pharmaceutical use?The key deal-breaker is failing to complete the Ministry of Health’s required import controls for products/raw materials of sanitary interest through the VUCE/PROCOMER system (for example, the NT57 workflow where applicable), which can prevent customs release or cause major delays.
Which tariff lines are commonly used for lactose in Costa Rica’s published tariff schedules, and what base rate is shown?Costa Rica tariff schedules list lactose under HS 17021100 (high-purity lactose) and HS 17021900 (other lactose), and published schedules show a base-rate context of 1% for these lines; the actual applied rate depends on correct classification and any preferential origin eligibility.
What specifications are typically expected for pharmaceutical-grade lactose used as an excipient?Supplier guidance commonly describes pharmaceutical-grade lactose as a high-purity powder with tight composition limits (e.g., lactose minimum around 99.8% with low protein/ash) and strict microbiological and impurity controls, and it is typically supplied in different particle-size grades depending on the application (such as tablets, capsules, or sachets).